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Abstract 
Background: Comorbid psychiatric disorders among opioid dependent patients are associated 
with several negative outcome factors. However, outcomes of maintenance treatment have not 
been sufficiently established, and no evidence is available with respect to heroin-assisted 
treatment (HAT). Methods: For patients in the German heroin trial outcome measures were 
analysed for HAT versus methadone maintenance treatment (MMT) both for patients with 
and without a comorbid diagnosis according to CIDI. Results: 47.2% of the sample had at 
least one comorbid psychiatric diagnosis, mainly neurotic, stress-related or somatoform (F4) 
or affective (F3) disorders. HAT had a better outcome than MMT concerning improvement of 
health and reduction of illicit drug use in both comorbid and non-comorbid patients, but 
weaker effects were found in the comorbid group. Conclusions: The better outcome of HAT 
also in comorbid patients suggests that psychiatric comorbidity should be an inclusion 
criterion for HAT. The weaker advantage of HAT may be due to pharmacological or 
methodological reasons.  
Keywords 
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Introduction 
Comorbid psychiatric disorders are common among opioid dependent patients undergoing 
maintenance treatment. Although comorbidity is difficult to diagnose and figures vary 
between the different studies, about 80% of patients with a diagnosis of drug dependence also 
have a comorbid psychiatric disorder, if personality disorders are included [1]. Comorbid 
opiate dependent patients have been found to have a higher use of non opiate drugs 
(benzodiazepines, alcohol, cannabis, and cocaine) [2], as well as a higher level of HIV risk 
taking behavior [3]. Personality disorders have also been found to be related to poorer social 
functioning among comorbid patients [4]. 
Few studies have analyzed the effects of psychiatric comorbid disorders on the outcome of 
maintenance treatment. Severity of psychological distress has been found to be negatively 
associated with treatment outcome for methadone maintenance treatment (MMT) patients 
with respect to benzodiazepine abuse, risk taking behaviors and prevalence of hepatitis C 
infection, but not with respect to opiate abuse [5]. Other studies showed a stronger correlation 
of comorbidity or severe mental illness with negative psychosocial outcomes, but not with 
higher illicit substance use [6-9]. Furthermore a comorbid mental disorder had no influence 
on the long-term course of drug dependence [10]. 
Heroin-assisted treatment (HAT), a relatively new form of maintenance treatment based on 
the philosophy of harm reduction, has been proposed for difficult-to-treat populations, with 
psychiatric comorbidity as one of the inclusion criteria. It has been implemented in clinical 
trials worldwide showing feasibility, effectiveness and safety [11]. However the response of 
patients with psychiatric comorbidity has not been evaluated separately in these studies, 
despite the high number of comorbid patients. In the Dutch study, for instance, 30% of 
patients were diagnosed to have a comorbid non-substance disorder [12, 13]. The Swiss study 
reported 41% of patients to have poor or very poor mental health and a high need for 
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psychological treatment [14]. In this study we used the data of the German heroin trial in 
order to assess the effects of comorbidity on the outcome of treatment. 
2. Methods 
2.1 The German project on heroin assisted treatment of opiate dependent patients 
HAT and MMT were compared in a multicenter trial among 1015 patients in 7 German cities. 
This intent to treat (ITT) sample resulted after screening 2038 heroin addicted patients, of 
which 1032 were randomised into four subgroups depending on type of medication (heroin or 
methadone) and psychosocial care received (psychoeducation plus individual counselling or 
case management plus motivational interviewing). Patients were recruited from two target 
groups: patients insufficiently responding to other maintenance treatments and patients not in 
treatment in the previous 6 months. Treatment duration was 12 months. The retention rate was 
67.2% for HAT patients compared with 40.0% for MMT patients. HAT patients received a 
maximum of three doses of intravenous diamorphine (heroin) per day (maximum daily dose 
of 1000 mg, average dose: 442 mg/d) with an additional (maximum of) 60 mg oral methadone 
when needed. MMT patients received one single dose of oral methadone daily which was 
individually adjusted according to clinical judgement (average dose: 99mg/d). Take-home 
methadone doses were only allowed in exceptional cases. Further details on randomization, 
treatment and outcome were published previously [15]. In a second 12-month phase of the 
study long-term effects of HAT were analysed [16]. 
2.2 Measures 
Besides sociodemographic data, assessment included self reported information on drug use 
and composite scores (ASI CS) according to the EuropASI [17]; based on the fifth edition of 
the Addiction Severity Index by [18]; German version: [19], psychopathology based on the 
health scale and Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-
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R, [20]), and the Composite International Diagnostic Interview (CIDI-10, [21]). Only the 
CIDI sections for ICD-10 group categories F2, F3, F4 and F5 were completed – personality 
disorders were not assessed due to the unreasonable interview length [22, 23]. Response was 
determined according to primary outcome measures (POM) for health improvement (at least 
20% improvement in the OTI health scale and/or at least 20% improvement in the GSI 
without a deterioration of more than 20% in the other area of health) and reduction of illicit 
drug use (reduction in the use of street heroin with at least 3 of 5 negative urines in the month 
prior to the end of the trial and no increase in cocaine use). Double-blind studies are not 
feasible when comparing oral methadone with intravenous diamorphine [24], among other 
reasons because the effect of intravenous diamorphine cannot be blinded and it is considered 
unethical for patients in the control group to inject a placebo agent, as injecting per se is 
considered to be a health risk. Therefore, a “worst case analysis” was used instead, where 
drop-outs in the control group (MMT) were considered responders and in the experimental 
group (HAT) were considered non-responders. Further details are described elsewhere [15]. 
2.3 Study population 
Figure 1 shows the distribution of the sample according to treatment completion and 
availability of CIDI diagnostics. The CIDI was administered one month after study treatment 
initiation, as the CIDI was not necessary for assessing inclusion and exclusion criteria. 
Furthermore, because of the length of the CIDI, a more stabilized treatment situation was 
considered to be more appropriate for this interview. A consequence of this procedure was 
missing data both due to drop-outs (144 MMT patients and 12 HAT patients abandoned 
treatment before initiation mainly due to disagreement with the randomization process) and 
non-attendance at the CIDI interview. A total of 626 patients were successfully interviewed. 
Of these, 485 completed the 12 months of treatment according to the study protocol (329 in 
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HAT, 156 in MMT). The analyses were carried out using this subsample of CIDI-interviewed 
completers. 
 Figure 1. Sample distribution by treatment completion and CIDI diagnosis for the last 12 
months. 
2.4 Statistical analysis 
T-tests and Chi square tests where used to compare characteristics of the sample between 
treatment groups in the total sample with CIDI interviews, the subsample of completers and 
between completers and non completers. Risk estimates and Mantel-Haenszel tests were used 
to estimate the odds ratios of meeting outcome criteria. Analyses of variance (ANOVA) and 
repeated measures analyses of variance (RMANOVA) were used to compare treatment groups 
with and without comorbid diagnoses at the beginning and the end of treatment with respect 
to ASI composite scores for drug use and psychiatric problems as well as GSI T-value scores.  
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3. Results 
3.1 Participant characteristics 
Table 1 shows the participants’ characteristics at initiation of treatment. No major differences 
were found between treatment groups in the whole CIDI sample or the subsample of 
completers. Nevertheless completers were older, had a stable housing situation more 
frequently and a slightly lower ASICS for drug misuse than non completers. 
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Table 1. Description of the CIDI sample (total sample, completers, and drop-outs) 
 Total CIDI interviews Completers with CIDI Drop-outs with CIDI Significance of 
differences between 
completers and drop-
outs* 
 HAT 
(N=421) 
MMT 
(N=205) 
Total 
(N=626) 
HAT 
(N=329) 
MMT 
(N=156) 
Total 
(N=485) 
HAT 
(N=92) 
MMT 
(N=49) 
Total 
(N=141) 
 
Female gender 
(%) 
21.14 22.44 21.57 19.76 24.36 21.24 26.09 16.33 22.70 2=.137, p=.711 
Age (mean±SD) 
36.31±6.59 36.57±6.76 36.40±6.64 36.61±6.68 36.85±7.03 36.69±6.79 35.25±6.15 35.67±5.76 35.40±6.00 t=2.035. p=.042 
Education in years 
(mean±SD) 
9.79±1.78 9.79±1.77 9.79±1.78 9.94±1.70 9.70±1.62 9.86±1.68 9.25±1.98 10.06±2.16 9.53±2.07 t=1.957, p=.051 
Employed (%) 
15.00 12.75 14.26 15.85 13.55 15.11 11.96 10.20 11.35 2=1.266, p=.261 
Stable housing 
(%) 
70.24 71.22 70.56 73.17 73.72 73.35 59.78 63.27 60.99 2=8.023, p=.005 
Years of heroin 
use (mean±SD) 
13.69±6.34 13.56±6.29 13.65±6.32 13.74±6.31 13.83±6.48 13.77±6.36 13.48±6.48 12.71±5.63 13.21±6.19 t=.926, p=.335 
Age of onset of 
heroin use 
(mean±SD) 
19.99±5.37 20.36±5.19 20.11±5.31 20.29±5.41 20.34±5.32 20.30±5.37 18.92±5.14 20.43±4.83 19.45±5.07 t=1.687, p=.092 
ASI CS for drug 
misuse (mean±SD) 
.38±.10 .39±.10 .39±.10 .38±.10 .38±.10 .38±0.10 .40±.11 .41±.10 .40±.11 t=-2.238, p=.026 
ASI CS for alcohol 
misuse (mean±SD) 
.12±.18 .12±.18 .12±.18 .12±.18 .13±.19 .12±0.18 .12±.19 .09±.13 .11±.17 t=.547, p=.566 
ASI CS for 
psychiatric 
problems 
(mean±SD) 
.23±.21 .23±.21 .23±.21 .23±.21 .23±.21 .23±0.21 .23±.18 .24±.22 .24±.20 t=-.289, p=.773 
GSI-SCL (T value) 
(mean ± SD) 
68.89±10.63 69.57±9.99 69.11±10.43 68.59±10.91 69.40±9.73 68.85±10.54 69.93±9.55 70.10±10.87 69.99±9.99 t=-1.142, p=.254 
 
*Statistically significant differences are marked in bold. 
HAT: Heroin Assisted Treatment MMT: Methadone Maintenance Treatment
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3.2 Comorbid mental disorders 
In the total sample (N=626) 306 patients (48.9%) were diagnosed with at least one additional 
mental disorder in the last 12 months. In the subsample of completers (N=485) 229 patients 
received an additional psychiatric diagnosis (47.2%). The proportion of comorbid patients did 
not differ significantly between HAT or MMT patients as well as completers or drop-outs. 
The distribution of comorbid diagnoses by CIDI categories in the subsample of completers is 
displayed in table 2. Neurotic, stress-related and somatoform disorder (F4) was the most 
frequent diagnosis and was more often diagnosed in MMT patients. Mood (affective) 
disorders (F3) were also common. Only a few patients were diagnosed with behavioural 
syndromes associated with physiological disturbances and physical factors (F5), and only 2 
patients with schizophrenia, schizotypal and delusional disorders (F2), with no significant 
differences between treatment groups regarding these categories. 
Table 2. CIDI-Diagnosis in the last 12 months by treatment group among completers  
 
Diagnostic category HAT 
(N=329) 
MMT 
(N=156) 
Total patients 
(N=485) 
Significance* 
 N % N % N %   
F20-F29 Schizophrenia, schizotypal and 
delusional disorders 
1 0.3 1 0.6 2 0.4 2=.293, 
p=.588 
F30-F39 Mood [affective] disorders 92 28.0 40 25.6 132 27.2 2=.288, 
p=.591 
F40-F48 Neurotic, stress-related and 
somatoform disorders 
88 26.7 64 41.0 152 31.3 2=10.025, 
p=.002 
F50-F59 Behavioural syndromes associated 
with physiological disturbances and physical 
factors 
5 1.5 6 3.8 11 2.3 2=2.584, 
p=.108 
No additional diagnosis (F20-F59) 180 54.7 76 48.7 256 52.8 2=1.525, 
p=.217 
 * Statistically significant differences are marked in bold. 
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3.3 Treatment retention 
Table 3 shows the rates of treatment retention according to treatment group and comorbidity. 
The slightly higher retention rate for HAT and non-comorbid patients was not significant. 
Table 3. Treatment retention by comorbidity group and treatment group. 
 
  Completers 
Drop-outs Significance treatment Significance 
comorbidity 
  N % N % No comorbid disorder: 
OR=1.16; 95% CI= .64-2.08 
Comorbid disorders: 
OR=1.06; 95% CI= .62-1.82 
Total (a):  
OR=1.11; 95% CI= .74-1.64 
HAT:  
OR=1.38; 95% CI= 
.87-2.19 
MMT:  
OR=1.27; 95% CI= 
.66-2.42 
Total (a):  
OR=1.34; 95% CI= 
.92-1.95 
No comorbid 
disorder  
HAT 180 80.72 43 19.28 
MMT 76 78.35 21 21.65 
Total 256 80.00 64 20.00 
At least one 
comorbid disorder 
HAT 149 75.25 49 24.75 
MMT 80 74.07 28 25.93 
Total 229 74.84 77 25.16 
 
 (a) Mantel-Haenszel tests 
 
3.4 Severity of symptomatology 
GSI-scores and ASI CS “psychiatric problems” are shown in table 4 according to treatment 
groups and comorbid versus non-comorbid patients in the subsample of CIDI-interviewed 
completers. Comorbid patients had significantly higher GSI T-values at beginning and end of 
treatment. No GSI differences were found between treatment groups at the beginning of 
treatment, but MMT patients had significant higher scores at the end. RM ANOVA showed a 
large time and treatment group effect, but no effect of comorbidity or interaction between 
comorbidity and treatment groups. A similar tendency could be observed concerning ASI CS 
for psychiatric problems. Comorbid patients also had higher scores at beginning and end of 
treatment, but no differences were found between treatment groups. Again, RM ANOVA 
showed significant time and between treatment group effects but no comorbidity or 
interaction effects. 
Page 11 of 17 
Table 4. Mental health (GSI T-value  and ASI CS composite scores for psychiatric problems) 
at baseline (t-1) and after 12 months of treatment (t12) in the per-protocol sample (N=485) 
by treatment and comorbidity group (CIDI-interviewed completers). 
 
  GSI T-value 
 CS psychiatric 
problems 
 
Baseline (t-1)   
Treatment significance 
(two factor RM 
ANOVA)* 
 
Treatment 
significance (two 
factor RM 
ANOVA)* 
No 
comorbidity 
HAT 66.35±11.35 
Time effect: 
Pillai’s Trace=.376, 
F=288.339,  df=1, 
p<.0001 
 
Treatment group effect: 
Pillai’s 
Trace=.008,F=3.994, 
df=1, p=.046 
 
Comorbidity effect: 
Pillai’s Trace=.003, 
F=1.243, df=1, p=.256 
 
Interaction treatment- 
comorbidity : 
Pillai’s Trace<.001, 
F=.163, df=1, p=.686 
 
.19±.21 
Time effect: 
Pillai’s 
Trace=.019, 
F=8.672, df=1. 
p=.003 
 
Treatment group 
effect: 
Pillai’s 
Trace=0.010, 
F=4.316,  df=1. 
p=.038 
 
Comorbidity 
effect: 
Pillai’s 
Trace<.001, 
F=.195, df=1. 
p=.659 
 
Interaction 
treatment- 
comorbidity : 
Pillai’s 
Trace=.002, 
F=.752, df=1, 
p=.386 
 
 MMT 66.46±10.18 .15±.16 
At least one 
comorbid 
diagnosis 
HAT 71.22±9.78 .28±.21 
 MMT 72.20±8.49 .30±.21 
Significance 
(two factor 
ANOVA) 
 
Treatment group 
effect: F=.301, 
p=.584 
Comorbidity 
effect: 
F=27.990,  
p<.001*** 
Treatment group 
effect: F=.332,  
p=.565 
Comorbidity 
effect: 
F=34.382,  
p<.001*** 
End of 
treatment (t12) 
   
No 
comorbidity 
HAT 54.66±13.68 .13±.18 
 MMT 56.67±13.16 .15±.20 
At least one 
comorbid 
diagnosis 
HAT 60.38±12.72 .23±.23 
 MMT 64.22±13.24 .28±.24 
Significance 
(two factor 
ANOVA) 
 
Treatment group 
effect: F=5.104, 
p=.024* 
Comorbidity 
effect: 
F=26.278. 
p<.001*** 
Treatment group 
effect: F=2.482, 
p=.116 
Comorbidity 
effect: 
F=27.777, 
p<.001*** 
*Statistically significant differences are marked in bold. 
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3.3 Treatment outcome/drug use 
Table 5 describes the course of ASI CS “drug use” in the subsample of CIDI-interviewed 
completers. Drug use was found to be significantly higher among patients with a comorbid 
diagnosis at the beginning and the end of treatment. The differences between treatment groups 
were not significant at the beginning, but highly significant at the end of treatment. The RM 
ANOVA showed time and treatment group effects, no effect of comorbidity, but an 
interaction between type of treatment and comorbidity indicating a slightly stronger 
improvement for comorbid patients in MMT compared to MMT-patients without 
comorbidity. Table 6 shows the distribution of responders according to the different outcome 
measures by treatment group and comorbidity, showing a significantly higher response for 
HAT compared to MMT, but with higher odds-ratios for the non-comorbid group. 
Table 5. ASI CS ”drug use” at baseline (t-1) and after 12 months of treatment (t12) in the 
per-protocol sample (N=485) by treatment and comorbidity group (CIDI-interviewed 
completers). 
  ASI CS “drug use” 
Significance treatment 
(two factor RM ANOVA)* 
Baseline (t-1)   Time effect: 
Pillai’s Trace=.594, F=624.373, 
df=1, p<.0001 
 
Treatment group effect: 
Pillai’s Trace=.186, F=97.367, 
df=1, p<.0001 
 
Comorbidity effect: 
Pillai’s Trace=.043, F=.043, df=1, 
p=.836 
Interaction treatment-comorbidity : 
Pillai’s Trace=.013, F=5.642, 
df=1, p=.018 
 
No comorbidity HAT .38±.10 
 MMT .35±.09 
At least one comorbid 
diagnosis 
HAT .38±.10 
 MMT .41±.09 
Significance (two factor 
ANOVA) 
 
Treatment group effect: F=.018,  
p=.892 
Comorbidity effect: F=8.991,  
p=.003 
End of treatment (t12)   
No comorbidity HAT .12±.10 
 MMT .27±.12 
At least one comorbid 
diagnosis 
HAT 0.16±.12 
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 MMT 0.29±.11 
Significance (two factor 
ANOVA) 
 
Treatment group effect: 
F=137.038, p<.0001 
Comorbidity effect: F=5.164, 
p=.018 
*Statistically significant differences are marked in bold. 
 
Table 6. Responders according to outcome measures by treatment group and comorbidity 
subsample (CIDI-interviewed completers). 
Outcome 
measure 
No comorbidity At least one comorbid diagnosis  
 HAT MMT Significance* HAT MMT Significance* Total 
significance* 
(a) 
 N % N % OR 95% 
CI 
N % N % OR 95% 
CI 
OR 95% 
CI 
Reduction 
of illegal 
drug use 
13
3 
73.
9 
3
7 
48.
7 
2.98
3 
1.705
-
5.219 
10
6 
71.
1 
4
5 
56.
3 
1.91
7 
1.088
-
3.378 
2.39
2 
1.608
-
3.558 
Improveme
nt of health 
16
0 
88.
9 
5
9 
77.
6 
2.30
5 
1.131
-
4.699 
12
6 
84.
6 
6
2 
77.
5 
1.59
0 
.800-
3.164 
1.89
4 
1.156
-
3.106 
*Statistically significant differences are marked in bold. 
(a)  Mantel-Haenszel Test between treatment groups by comorbidity. 
 
Discussion 
As HAT is considered a second line maintenance treatment for difficult-to-treat opioid 
dependent patients, more evidence is needed to help clinicians identify suitable patients. All 
data from HAT trials published so far have not provided any evidence on the indication and 
outcome of heroin maintenance in patients with psychiatric comorbidity.   
The presented study revealed treatment group effects between HAT and MMT in both 
patients with and without psychiatric comorbidity. The findings suggest that HAT is superior 
to MMT with regard to improvement of health and reduction of illicit drug use also in patients 
Page 14 of 17 
with psychiatric comorbidity. However, psychiatric comorbidity had an influence on the 
strength of treatment group effects: While comorbidity status had no effect on the decrease of 
both mental health scores or the ASI CS for drug use over time, the odds-ratios of response 
rates were higher for non-comorbid patients compared to those with psychiatry comorbidity.  
The less distinct benefit of HAT in patients with psychiatric comorbidity may be due to 
several reasons. First, patients with anxiety or depressive disorders may benefit from the 
sedative effect of methadone, which is not a property of diamorphine. Second, the overall 
lower treatment effect in the group with psychiatric comorbidity, regardless of the type of 
treatment, make differences between treatment groups less apparent. This is in line with the 
well known result of a lower effectiveness of addiction treatment in the presence of 
psychiatric comorbidity.  
A limitation of the study is the fact that, due to the requirements of a controlled clinical trial, 
patients with a very severe mental disorder had to be excluded. This explains the surprisingly 
low number of patients with a schizophrenia spectrum disorder. This subsample should be 
analysed in the future, when more patients have been included in HAT. The same refers to 
patients with personality disorders, which were not assessed in the German HAT trial. 
Previous studies indicated that personality disorders might be related to specific problems 
among comorbid patients [4], and it cannot be excluded that this type of comorbidity has 
additional effects on the outcome of both MMT and HAT. Another limitation is related to the 
fact that subjects were not blind to the type of treatment after randomization. It remains 
unclear whether the higher rate of patients that dropped out after being randomized to MMT 
had any effects on the results of the study. It could also be argued, that the fact that patients 
were aware of the type of treatment might have had an impact on outcome in favour of heroin 
treatment. However, to control for such effects, a “worst case analysis” was used where drop-
outs in the control group (MMT) were considered responders and in the experimental group 
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(HAT) were considered non-responders. Finally, patients in the MMT group had a 
significantly higher number of anxiety disorders according to the CIDI as compared to the 
HAT group. However, both GSI and EuropASI scores revealed no differences in the severity 
of psychiatric impairment between both groups. 
In conclusion, the results of our study indicate that psychiatric comorbidity can be considered 
an additional inclusion criterion for HAT. In clinical routine, comorbid patients may benefit 
from the more structuring nature of HAT, requiring three clinical contacts per day. However, 
as the amount of additional psychosocial care was controlled for in this study [15], it can be 
assumed that the differences in outcome are to a certain extent related to the type of 
pharmacological treatment. Nevertheless, the primary aim of both MMT and HAT is to 
decrease drug use by making another substance available. In comorbid patients, where 
psychiatric symptoms and substance use are often interrelated, they need to be accompanied 
by more specific psychiatric interventions to bring about more far reaching treatment effects. 
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